Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations From MGTA-117 Clinical Trial and Other Program Highlights

Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS National Biotechnology Conference

Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights